$XPOF

Xponential Fitness, Inc. (XPOF): Results of Operations and Financial Condition

Xponential Fitness, Inc. (XPOF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d328551dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Xponential Fitness, Inc. Announces Second Quarter 2026 Financial Results - North America system-wide sales 1 of $437.3 million were flat year-over-year - Opened 67 gross new studios and sold 53 franchise licenses in Q2 2026

Original reporting
Published Aug 6, 2026, 8:59 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$XPOF
Bearish
high confidence
Mentioned
$XPOF
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$XPOFBearishHigh
01

Why it matters

The 8-K provides a fresh earnings datapoint plus a revised 2026 outlook, which can drive repricing of forward growth and margin expectations. Key disclosed drivers include fewer equipment installations, merchandise revenue collapse tied to the outsourced retail model transition, and higher legal and marketing fund expenses.

02

Market read

Traders can act on the guidance reset: full-year revenue and adjusted EBITDA ranges were lowered, and Q2 showed net loss and weaker adjusted EBITDA versus the prior year.

03

What to watch

The company attributes revenue declines to fewer equipment installations and a logistics model transition, so investors may differentiate operational transition effects from underlying franchise demand.

Relevance 7/10Novelty 9/10Timing: after-hours filing and before the 1:30 p.m. PT conference call

Background

Xponential Fitness is a global franchisor of boutique health and wellness brands and reports quarterly revenue, franchise KPIs, and adjusted profitability metrics.

Company-level read

Ticker impact

$XPOFBearishHigh confidence
Context

Xponential reported Q2 2026 results and revised full-year 2026 outlook, including lower revenue and adjusted EBITDA guidance.

Expected impact

Near-term volatility likely as investors reprice FY 2026 revenue and adjusted EBITDA expectations.

Evidence & confidence

The filing discloses a 13% revenue decline, net loss, adjusted EBITDA down 22% YoY, and a full-year outlook reduction versus prior guidance.

Market effects

Boutique fitness franchisors may face read-across pressure if investors interpret the outsourced logistics transition and same-store weakness as margin headwinds.

North America KPIs (system-wide sales flat, same-store sales down) are the primary driver, suggesting regional demand softness.

International studio growth remains a stated priority, but the outlook cut implies global execution risk despite expansion plans.

Counterpoint

Management frames results as progress on long-term priorities (studio growth, digital capabilities, franchisee support), implying the guidance cut could be temporary from transition costs.

Key entities

  • Xponential Fitness, Inc.

    Reported Q2 2026 financial results and revised full-year 2026 outlook in an SEC 8-K.

  • Mike Nuzzo

    CEO quoted on progress against long-term priorities despite Q2 results below expectations.

Related articles

$XPOFHighAI 9/10

Why Xponential Fitness (XPOF) Shares Are Falling Today

Xponential Fitness (NYSE: XPOF) shares fell about 22.5% after its Q2 adjusted EPS of $0.02 missed consensus near $0.13 and the company cut full-year guidance. Revenue was about $66M, down 13% YoY, with same-store sales down 6.8%. FY 2026 revenue guidance was lowered to $250–$260M and adjusted EBITDA to $91–$97M.

$XPOFHighAI 9/10

Why is Xponential Fitness stock plunging today?

Xponential Fitness (XPOF) shares fell about 22% in pre-open after Q2 2026 results missed profitability expectations. Revenue was $66M vs $64.43M consensus, but adjusted EPS was $0.02, about 83% below the $0.12 forecast. Adjusted EBITDA fell 22% to $21.9M. Management cut FY 2026 revenue to $250–$260M and EBITDA to $91–$97M, and Guggenheim downgraded the stock.

$XPOFMedAI 8/10

Strategic Update on Xponential Fitness (XPOF)

Voss Capital’s Q1 2026 investor letter said its Voss Value Fund returned -11.4% and the Voss Value Offshore Fund returned -11.5% net of fees, versus gains for the Russell 2000 and Russell 2000 Value and a -4.3% S&P 500. The firm highlighted Xponential Fitness (XPOF), citing a strategic review after it urged a valuation gap fix. XPOF closed May 29, 2026 at $5.49; Q1 revenue fell to $60.7 million from $76.9 million.

$DRIMedAI 8/10

DRI Healthcare Reports Second Quarter 2026 Results and New Board Appointment

DRI Healthcare Trust (TSX: DHT.UN, DHT.U) reported Q2 2026 results for the quarter ended June 30, 2026: total income $50.1M, total cash receipts $46.5M, and adjusted EBITDA $42.6M. It repurchased 89,513 units at $11.65 and paid a $0.11/unit distribution. After quarter-end, it exercised a put option on Ekterly for about $178M and received FDA approval for Lumvoa (veligrotug), triggering $75M milestone payments.

$LGNDMed

Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary

Ligand Pharmaceuticals reported Q2 2026 results and discussed its XOMA Royalty acquisition, adding 120+ assets and extending cash flow duration through 2040. Management cited 32% YoY royalty revenue growth and expects 2026 royalty revenue of $225M-$250M with cash opex halved since 2022. Ligand issued a $700M zero-coupon convertible, raised 2026 adjusted EPS guidance to $9.00-$9.50, and expects accretion from XOMA in 2H26 and 2027.